• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Gold nanoparticle-conjugated antibody-drug conjugates for HER2-positive gastric cancer with heterogeneity

Research Project

  • PDF
Project/Area Number 19K09148
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 55020:Digestive surgery-related
Research InstitutionOkayama University

Principal Investigator

Kuroda Shinji  岡山大学, 大学病院, 助教 (60633758)

Project Period (FY) 2019-04-01 – 2022-03-31
Keywords金ナノ粒子 / 抗体薬物複合体 / 胃癌 / HER2 / 組織不均一性 / バイスタンダー効果
Outline of Final Research Achievements

Gold nanoparticle-conjugated trastuzumab emtansine (T-DM1) (ATDM1) produced potent cytotoxic effects on HER2-positive gastric cancer cells compared to T-DM1 by enhanced HER2-dependent incorporation into cells. Moreover, ATDM1 also produced strong cytotoxic effects on surrounding HER2-negative gastric cancer cells via bystander effect. These findings indicate that conjugation of gold nanoparticles with T-DM1 can be a promising treatment strategy to overcome heterogeneity in gastric cancer.

Free Research Field

消化器外科

Academic Significance and Societal Importance of the Research Achievements

胃癌治療の課題のひとつが組織不均一性の克服であるが、本研究成果は、乳癌で主に臨床使用されている抗体薬物複合体であるT-DM1に金ナノ粒子を結合させることで、HER2陽性の標的細胞への薬物送達を向上させることができ、さらにバイスタンダー効果を介してその周囲の非標的細胞にも治療効果を期待できることから、組織不均一性を有する胃癌などの癌腫に対する新規治療薬の開発につながる可能性を秘めたものと考えられる。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi